MOUNTAIN VIEW, Calif.--(BW HealthWire)--Feb. 25, 1999--VIVUS,
Inc. (Nasdaq:VVUS) today announced that the Company has received
notification that the license necessary for the launch of MUSE(R)
(alprostadil) in Germany has been granted. This license triggers a $2
million milestone payment to VIVUS from ASTRA. Several additional
European Union countries have recently issued licenses for MUSE,
including Denmark, The Netherlands, Ireland, Luxembourg and Finland.
Currently, ASTRA is planning to launch MUSE in these countries during
the second quarter of 1999.
Founded in 1991, VIVUS, Inc. is a leader in the development of
advanced therapeutic systems for the treatment of erectile
dysfunction, commonly referred to as impotence. VIVUS has pioneered a
novel therapy for erectile dysfunction known as the transurethral
system for erection. This therapy consists of a proprietary,
non-invasive drug delivery system that delivers pharmacologic agents
via the urethra.
Note to editors and investors: Additional written materials,
recent releases and Company information are available through a
variety of sources, including the VIVUS home page (www.vivus.com) and
the VIVUS Fax-On-Demand Service (1-888-329-5719).
CONTACT: VIVUS, Inc., Mountain View
Nina W. Ferrari, 650/934-5200 (Director, Corp. Comm.)
IR@VIVUS.com |
